Score Overview
Explore the 2021 public Archive ranking →
Where Haemonetics Corporation has ranked, year by year
Showing 5 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- HAE
1997: 42.7% · 2021: 12.6% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 105.80 | — |
1 Year2025-09-29 | $ 48.12 | 119.87% |
5 Years2021-09-29 | $ 70.46 | 50.16% |
10 Years2016-09-29 | $ 35.71 | 196.28% |
20 Years2006-09-29 | $ 23.40 | 352.14% |
30 Years1996-09-27 | $ 10.56 | 10x |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | 30 Years1996-09-27 |
|---|---|---|---|---|---|---|
| Price | $ 105.80 | $ 48.12 | $ 70.46 | $ 35.71 | $ 23.40 | $ 10.56 |
| Return | — | 119.87% | 50.16% | 196.28% | 352.14% | 10x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 1.35B | $ 96M | $ 223M |
| 2026 | $ 1.33B | $ 97M | $ 245M |
| 2025 | $ 1.36B | $ 167M | $ 306M |
| 2024 | $ 1.30B | $ 117M | $ 178M |
| 2023 | $ 1.16B | $ 115M | $ 284M |
| 2022 | $ 993M | $ 43M | $ 259M |
| 2021 | $ 870M | $ 79M | $ 192M |
| 2020 | $ 988M | $ 76M | $ 137M |
| 2019 | $ 967M | $ 55M | $ 169M |
| 2018 | $ 903M | $ 45M | $ 180M |
| 2017 | $ 886M | -$ 26M | $ 139M |
| 2016 | $ 908M | -$ 55M | $ 115M |
| 2015 | $ 910M | $ 16M | $ 160M |
| 2014 | $ 938M | $ 35M | $ 192M |
| 2013 | $ 891M | $ 38M | $ 179M |
| 2012 | $ 727M | $ 66M | $ 228M |
| 2011 | $ 676M | $ 79M | $ 196M |
| 2010 | $ 645M | $ 58M | $ 141M |
| 2009 | $ 597M | $ 59M | $ 156M |
| 2008 | $ 516M | $ 51M | $ 133M |
| 2007 | $ 449M | $ 49M | $ 229M |
| 2006 | $ 419M | $ 69M | $ 250M |
| 2005 | $ 383M | $ 39M | $ 185M |
| 2004 | $ 364M | $ 29M | $ 118M |
| 2003 | $ 336M | $ 28M | $ 49M |
| 2002 | $ 319M | $ 30M | $ 67M |
| 2001 | $ 293M | $ 7M | $ 74M |
| 2000 | $ 277M | $ 18M | $ 61M |
| 1999 | $ 282M | $ 21M | $ 56M |
| 1998 | $ 285M | -$ 24M | $ 21M |
| 1997 | $ 309M | $ 33M | $ 8M |
| 1996 | $ 278M | $ 35M | $ 13M |
| 1995 | $ 262M | $ 33M | $ 4M |
| 1994 | $ 248M | $ 31M | $ 16M |
| 1993 | $ 216M | $ 24M | $ 10M |
| 1992 | $ 176M | $ 18M | $ 2M |
Haemonetics Corporation fundamental performance
Between 2021 and 2026, revenue grew from $ 870M to $ 1.33B and net income grew from $ 79M to $ 97M. Revenue increased in 4 of those 5 years; net income in 3.
Between 2016 and 2026, revenue grew from $ 908M to $ 1.33B and net income went from -$ 55M to $ 97M. Revenue increased in 8 of those 10 years; net income in 7.
Haemonetics Corporation currently holds a 20-year HDB Score of 5.1 out of 10. How the HDB Score is calculated.
Membership
Continue HAE’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
